Zelda Therapeutics Limited ("Zelda") is an Australian biotechnology company which listed on the Australian Stock Exchange (ASX) in 2016, trading under the ASX code "ZLD". The company is developing medicinal cannabis therapies in collaboration with a number of key international leaders and research organisations. Zelda has exclusive access to comprehensive patient data that has demonstrated therapeutic success using cannabinoid-based treatments and has leveraged this to commence pre-clinical research in breast, brain and pancreatic cancer and will commence human clinical trials in 2017 on a number of other disorders including insomnia and dermatological conditions such as eczema.

Please click here to download the Zelda Factsheet

To keep updated with investement news or for information on buying shares please email

enquiries@zeldatherapeutics.com